Aimei Health Technology Co., Ltd (AFJK)

NASDAQ: AFJK · USD

$12.0

-0.09 (-0.8%)· Recorded snapshot

Market cap	37.9M
Net income (ttm)	412.4K
EPS (ttm)	$0.09
Shares out	3.2M
P/E (trailing)	127.8x
Volume	345
Beta	0.91

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): 412.4K
EPS (ttm): $0.09
P/E (trailing): 127.8x
Market cap: 37.9M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ACGL	Arch Capital Group Ltd.	34.8B	8.3x	1.8x	15.9%	+15.1%	+18.7%	ซื้อมาก
AIG	American International Group Inc.	41.7B	14.7x	1.6x	7.7%	-9.6%	+2.8%	ซื้อมาก
AIZ	Assurant, Inc.	14.1B	13.6x	1.0x	14.4%	+6.6%	+36.2%	ถือ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/E127.8

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROICn/a

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All AFJK indicators

Market & fundamental data

Available fields

154

Groups with data

Currency

USD

Showing 154 of 154 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001979005
Company name	Aimei Health Technology Co., Ltd
Country	United States
Country code	US
CUSIP number	G01341109
Earnings date	2026-11-17
Earnings time	amc
Enterprise value	$41.2M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2023
Industry	Shell Companies
IPO date	2023-12-04
Is primary listing	Yes
Is SPAC	Yes
ISIN number	KYG013411098
Last 10-K release date	2026-05-04
Last earnings date	2026-08-13
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$37.9M
Market cap category	Nano-Cap
Next earnings date	2026-11-17
Options	No
Price	$11.96
Price currency	USD
Sector	Financials
SIC code	6770
Stock price date	2026-10-28
Symbol	AFJK
U.S. state	New York

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Average P/E ratio (3Y)	121.86x
Earnings yield	0.78%
EV/Earnings	100.26x
FCF / EV yield	-1.73%
FCF yield	-1.89%
Industry P/E	94.86x
P/E ratio	127.79x
Sector forward P/E	13.61x
Sector P/E	15.68x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profitable years	2
ROA	-1.39%
ROCE	-7.31%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-59.06%
EPS growth years	0
Net income growth	-77.05%
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
EBIT	$-635,073
EPS	$0.09
FCF per share	$-0.23
Financing cash flow	$-32.7M
Free cash flow	$-716,999
Investing cash flow	$33.1M
Net borrowing	$1.4M
Net cash flow	$-672
Net income	$412,432
Operating income	$-635,073

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$-1.42
Long-term assets	$12.5M
Long-term liabilities	$13.2M
Net cash (debt)	$-3.3M
Net cash / market cap	-8.74%
Piotroski F-Score	1
Shareholders' equity	$-4.5M
Tangible book value	$-4.5M
Tangible book value per share	$-1.42
Total assets	$12.5M
Total cash	$1,466
Total debt	$3.3M
Total liabilities	$17M
WACC	8.5%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$43,966
Current liabilities	$3.8M
Current ratio	0.01
Net working capital	$-470,816
Quick ratio	0
Working capital	$-3.8M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	43.95%
Dividend yield	0%
Shareholder yield	43.95%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$24.91
1D price change	-0.75%
1M price change	-1.89%
1M total return	-1.89%
1W price change	-1.16%
1W total return	-1.16%
1Y price change	5.56%
1Y return CAGR	5.56%
1Y total return	5.56%
20-day SMA	$12.20
200-day SMA	$31.38
3M price change	1.01%
3M total return	1.01%
50-day SMA	$12.18
50-day SMA vs 200-day SMA	50under200
52-week high	$130.37
52-week high date	2025-12-31
52-week low	$6.75
52-week low date	2025-12-04
6M price change	-73.36%
6M total return	-73.36%
All-time high	$130.37
All-time high date	2025-12-31
All-time low	$6.75
All-time low date	2025-12-04
Average true range (ATR)	$0.25
Average volume	1.6K
Beta (1Y)	0.66
Beta (2Y)	0.22
Beta (5Y)	0.91
Change from 52-week high	-90.83%
Change from 52-week low	77.19%
Change from all-time high	-90.83%
Change from all-time low	77.19%
Change from open	-0.42%
Day's gap	-0.33%
Dollar volume	$4,126
High price	$12.53
Low price	$12.01
Monthly RSI	44.96
Open price	$12.01
Position in 52-week range	0%
Premarket change	-1.08%
Premarket close	$12.05
Premarket price	$11.92
Previous close	$12.05
Price vs 150-day SMA	-51.99%
Price vs 20-day SMA	-1.98%
Price vs 200-day SMA	-61.89%
Price vs 50-day SMA	-1.77%
Relative volume	0.21
Return from IPO price	20.1%
RSI	41.26
Sharpe ratio	0.99
Sortino ratio	8.35
Volume	345
Weekly RSI	35.41
YTD price change	-81.32%
YTD total return	-81.32%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1.1M
Float percentage	35.04%
Shares change (QoQ)	0%
Shares change (YoY)	-43.95%
Shares held by insiders	64.96%
Shares held by institutions	30.99%
Shares outstanding	3.2M
Short % of float	0.2%
Short % of shares	0.07%
Short ratio	0.1 days

Deeper analysis on AFJK

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this AFJK report

Is a complete AFJK research report available?

No complete published report is available for Aimei Health Technology Co., Ltd (AFJK) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Aimei Health Technology Co., Ltd (AFJK)

Price

Financial snapshot

Fair-value bridge

Latest news · AFJK

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All AFJK indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on AFJK

Frequently asked questions